Clinical trial · Interventional
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
NCT01453504CI-TRIAL-00041534HD-R3icompletedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this trial is 1. to determine the recommended dose of everolimus for a subsequent Phase II trial 2. to determine the efficacy of everolimus plus DHAP
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DHAP | Drug | — | UNRESOLVED |
| Everolimus | Drug | Everolimus | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Ever-DHAP
- description
- Combination of Everolimus and DHAP
- interventionNames
- Drug: DHAP
- Drug: Everolimus
- type
- PLACEBO_COMPARATOR
- label
- Placebo-DHAP
- interventionNames
- Drug: DHAP
Primary outcomes (2)
- measure
- Dose Limiting Toxicity Rate (DLT)
- timeFrame
- 4 weeks
- description
- Phase I primary outcome measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * relapsed or refractory Hodgkin Lymphoma * age 18-60 * histology confirmed relapse Exclusion Criteria: * previous therapy with mTOR inhibitor * current CNS involvement * other primary malignant disease within the last 3 years
References
Publications (0)
Data not yet available
No reference posted for this study.